Grant: Doctoral: Vanier Canada Graduate Scholarships
McMaster University
$150,000.00
Allosteric modulation of the dopamine D2 receptor: A new perspective for the treatment of schizophrenia.
FY 2013-14
Summary
Schizophrenia is a serious mental disorder that affects over 330,000 people in Canada. This mental illness can manifest in various ways, and is often characterized by the appearance of positive symptoms (hallucinations), negative symptoms (social and attention impairment) and cognitive dysfunction (memory impairment). Traditional treatment methodologies involve blocking the dopamine receptor by binding to the same site as dopamine. This mechanism of action is similar to a light switch with an absolute "on and off" effect. These treatments are largely inadequate and lead to an array of severe adverse side effects; including weight gain, diabetes, and movement disorders that critically limit the therapeutic value of current antipsychotic treatment. A lack of effective symptom control and severe side effects have led to poor drug adherence and a deprived quality of life for patients with schizophrenia. Evidently, there is a strong demand for a new generation of therapy to effectively treat schizophrenia. Allosteric technology is evolving as a new wave of therapy with promising implications for various mental disorders. Allosteric compounds regulate dopamine binding without blocking the receptor. This action is similar to a dimmer switch and can subtly modulate output with the desired intensity. Utilizing allosteric technology we have developed a new a line of drugs with the ability to effectively modulate dopamine binding. PAOPA, a potent and specific allosteric modulator, has been shown to prevent and treat schizophrenia-like symptoms in pre-clinical animal models of schizophrenia with no adverse effects. The studies outlined in this proposal aim to further categorize the therapeutic potential of PAOPA and progress the development of this compound to clinical studies. Ultimately, it is envisioned that this technology will allow physicians to not only treat the symptoms in question, but also treat schizophrenia prior to the development of full-blown psychosis.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
299984
Name
Daya Ritesh
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Allosteric modulation of the dopamine D2 receptor: A new perspective for the treatment of schizophrenia.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Allosteric Modulator; Dopamine D2 Receptor; Preclinical Model; Schizophrenia
Abstract
Schizophrenia is a serious mental disorder that affects over 330,000 people in Canada. This mental illness can manifest in various ways, and is often characterized by the appearance of positive symptoms (hallucinations), negative symptoms (social and attention impairment) and cognitive dysfunction (memory impairment). Traditional treatment methodologies involve blocking the dopamine receptor by binding to the same site as dopamine. This mechanism of action is similar to a light switch with an absolute "on and off" effect. These treatments are largely inadequate and lead to an array of severe adverse side effects; including weight gain, diabetes, and movement disorders that critically limit the therapeutic value of current antipsychotic treatment. A lack of effective symptom control and severe side effects have led to poor drug adherence and a deprived quality of life for patients with schizophrenia. Evidently, there is a strong demand for a new generation of therapy to effectively treat schizophrenia. Allosteric technology is evolving as a new wave of therapy with promising implications for various mental disorders. Allosteric compounds regulate dopamine binding without blocking the receptor. This action is similar to a dimmer switch and can subtly modulate output with the desired intensity. Utilizing allosteric technology we have developed a new a line of drugs with the ability to effectively modulate dopamine binding. PAOPA, a potent and specific allosteric modulator, has been shown to prevent and treat schizophrenia-like symptoms in pre-clinical animal models of schizophrenia with no adverse effects. The studies outlined in this proposal aim to further categorize the therapeutic potential of PAOPA and progress the development of this compound to clinical studies. Ultimately, it is envisioned that this technology will allow physicians to not only treat the symptoms in question, but also treat schizophrenia prior to the development of full-blown psychosis.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Daya, Ritesh
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~